The National Institutes of Health (NIH) announced another potential breakthrough in the fight against Zika on Thursday.
The NIH will soon begin the first-in-human trial of a live, attenuated Zika virus vaccine. The tests will take at centers at Johns Hopkins University and the University of Vermont. The clinical trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), the branch of the NIH which developed the vaccine.
Subjects will be 28 healthy, non-pregnant adults ages 18 to 50.